Patents by Inventor Dennis M. Brown

Dennis M. Brown has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200206188
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutically active agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to therapeutically active agents selected from the group consisting of: (i) indirubin; (ii) an analog of indirubin; (iii) a derivative of indirubin or of an analog of indirubin; and (iv) a pharmaceutical composition comprising indirubin, an analog of indirubin, or a derivative of indirubin or of an analog of indirubin, especially meisoindigo.
    Type: Application
    Filed: August 19, 2019
    Publication date: July 2, 2020
    Inventors: Dennis M. BROWN, Ian NISBET
  • Publication number: 20200062839
    Abstract: Methods and compositions employing dianhydrogalactitol or a derivative or analog of dianhydrogalactitol together with a vascular endothelial growth factor (VEGF) inhibitor or other anti-neoplastic agents can be used for treatment of glioma. In particular, methods and compositions according to the invention can decrease the invasiveness of gliomas. Further disclosed are methods of using the compositions for treating a malignancy that has failed a VEGF inhibitor treatment.
    Type: Application
    Filed: May 1, 2018
    Publication date: February 27, 2020
    Inventors: Jeffrey A. BACHA, Dennis M. BROWN, Anne STEINØ
  • Publication number: 20200061054
    Abstract: Methods and compositions employing dianhydrogalactitol or a derivative analog of dianhydrogalactitol together with a p53 modulator, a PARP inhibitor, or topoisomerase inhibitor for treatment of malignancies are provided.
    Type: Application
    Filed: February 28, 2018
    Publication date: February 27, 2020
    Applicant: Del Mar Pharmaceuticals (BC) Ltd.
    Inventors: Jeffrey A. Bacha, Dennis M. Brown, Anne Steinø, Mads Daugaard, Beibei Zhai
  • Publication number: 20200040409
    Abstract: The present disclosure is in the field of plant breeding. The disclosure provides methods for breeding corn plants having a brachytic trait using marker-assisted selection. The disclosure further provides brachytic germplasm, markers associated with a brachytic trait for introgressing the trait into elite germplasm in a breeding program. This disclosure also provides brachytic or dwarf elite corn varieties having yield equal to or higher than conventional non-brachytic corn varieties.
    Type: Application
    Filed: October 1, 2019
    Publication date: February 6, 2020
    Applicant: Monsanto Technology LLC
    Inventors: Ty Jason Barten, Alana N. Brown, Edward James Cargill, Romain Fouquet, Jose Rafael Gomez, Matthew Sean Marengo, Manuel Oyervides Garcia, Jeanette M. Peevers, Dennis Hung Yang
  • Patent number: 10536130
    Abstract: A single input multiple output plasma control system includes a splitter that receives a single input and generates multiple outputs. Each output from the splitter is provided to a load. The splitter includes branch circuits connected between selected splitter outputs. The branch circuits control voltage, current, power, frequency, or phase between each branch to enable controlling a predetermined relationship between the voltage, current, power, impedance, frequency, or phase measured at each load.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: January 14, 2020
    Assignee: MKS Instruments, inc.
    Inventors: David J. Coumou, Dennis M. Brown, Jeongseok Jang, Jin Huh
  • Patent number: 10495083
    Abstract: A pushrod assembly 5 may include a seal carrier 50 for a spaced seal assembly 60 and/or a seal carrier 70 for a stacked seal assembly 74, the spaced seal assembly including first and second annular seals 61, 62 separated by a spacer 63 to isolate between the seals a vented region 28 of the pushrod housing 6, the stacked seal assembly including at least two annular seals 80 stacked on the seal carrier. Each seal assembly can be removed and replaced via an access end 52, 72 of the seal carrier after detaching the access end from an adjacent component of the assembly. The seal carriers may be incorporated into a cryogenic pump 2 wherein at least one annular seal is arranged on each seal carrier to seal the pushrod assembly 5 within its housing 6.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: December 3, 2019
    Assignee: Caterpillar Inc.
    Inventors: Alan Stockner, Aaron M. Brown, Sridhar Thangaswamy, Dana R. Coldren, Dennis Gibson
  • Patent number: 10472684
    Abstract: The present disclosure is in the field of plant breeding. The disclosure provides methods for breeding corn plants having a brachytic trait using marker-assisted selection. The disclosure further provides brachytic germplasm, markers associated with a brachytic trait for introgressing the trait into elite germplasm in a breeding program. This disclosure also provides brachytic or dwarf elite corn varieties having yield equal to or higher than conventional non-brachytic corn varieties.
    Type: Grant
    Filed: April 27, 2016
    Date of Patent: November 12, 2019
    Assignee: Monsanto Technology LLC
    Inventors: Ty Jason Barten, Alana N. Brown, Edward James Cargill, Romain Fouquet, Jose Rafael Gomez, Matthew Sean Marengo, Manuel Oyervides Garcia, Jeanette M. Peevers, Dennis Hung Yang
  • Publication number: 20190269646
    Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.
    Type: Application
    Filed: May 12, 2015
    Publication date: September 5, 2019
    Inventors: Jeffrey A. BACHA, Dennis M. BROWN, Anne STEINØ
  • Patent number: 10383847
    Abstract: The present invention describes methods and compositions for improving the therapeutic efficacy of therapeutically active agents previously limited by suboptimal therapeutic performance by either improving efficacy as monotherapy or reducing side effects. Such methods and compositions are particularly applicable to therapeutically active agents selected from the group consisting of: (i) indirubin; (ii) an analog of indirubin; (iii) a derivative of indirubin or of an analog of indirubin; and (iv) a pharmaceutical composition comprising indirubin, an analog of indirubin, or a derivative of indirubin or of an analog of indirubin, especially meisoindigo.
    Type: Grant
    Filed: April 11, 2014
    Date of Patent: August 20, 2019
    Inventors: Dennis M. Brown, Ian Nisbet
  • Publication number: 20190248080
    Abstract: Packaging apparatus for producing encased products from flat-roll stock using an external user interface (i.e., a handle that is external to a housing holding the heat seal assembly that is attached to a horizontally oriented shaft that rotates a first gear in the housing to rotate an aligned second gear in the housing or an electronic control) that is attached to and/or in communication with (directly or indirectly) a heat-seal assembly with a heat-seal contact member, such as a heat-seal band, in the housing to allow a user to adjust a vertical height of the heat-seal assembly while the apparatus is operational and/or without requiring physical access to the interior of the housing.
    Type: Application
    Filed: February 11, 2019
    Publication date: August 15, 2019
    Applicant: Tipper Tie, Inc.
    Inventors: Samuel D. Griggs, Dennis J. May, Derek L. Brown, William M. Poteat
  • Patent number: 10344472
    Abstract: A tubular passage for poured concrete decks has an intumescent tube held in a two-part, clamshell base by a bottom clip. A first tube engages the base's top to clamp a funnel shaped, diaphragm seal to the base. The first tube has spaced, radially extending, parallel ridges at predetermined distances from the base. Longitudinal channels separate the ridges. An extension tube has inward extending lugs passing along the channels to engage various ridges when rotated to fix the passage length. The extension engages the base bottom for corrugated deck supports. A cap with repositionable, locating filaments closes either tube.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: July 9, 2019
    Assignee: Reliance Worldwide Corporation
    Inventors: Timothy M. McConnell, Virgil O'Neil, Larry D. Brown, Dennis L. Hart, Darrell W. Price
  • Publication number: 20190183843
    Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.
    Type: Application
    Filed: June 15, 2017
    Publication date: June 20, 2019
    Inventors: Jeffrey A. BACHA, Dennis M. BROWN, Anne STEINØ
  • Publication number: 20190175541
    Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of malignancies of the central nervous system in pediatric patients, including glioblastoma multiforme (GBM) high grade glioma, and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation and that can induce double-stranded breaks in DNA. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents (e.g. cisplatin) and can possess additive or super-additive effects.
    Type: Application
    Filed: October 26, 2016
    Publication date: June 13, 2019
    Applicant: DelMar Pharmaceuticals, Inc.
    Inventors: Jeffrey A. Bacha, Dennis M. Brown, Anne Steinø
  • Patent number: 10304669
    Abstract: An RF generator in a dual frequency RF generation system. The RF generator detects IMD components resulting from interaction of the two frequencies. The IMD is reduced by adjusting the phase of the RF signal output by the RF generator. In various configurations, the IMD may also be reduced by applying a power adjustment value.
    Type: Grant
    Filed: January 21, 2018
    Date of Patent: May 28, 2019
    Assignee: MKS Instruments, Inc.
    Inventors: David J. Coumou, Dennis M. Brown, Eldridge M. Mount, IV
  • Publication number: 20190142783
    Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
    Type: Application
    Filed: January 8, 2019
    Publication date: May 16, 2019
    Applicant: Del Mar Pharmaceuticals (BC) Ltd.
    Inventors: Dennis M. Brown, Jeffrey Bacha, Sandra Dunn
  • Patent number: 10269546
    Abstract: An RF generator in a dual frequency RF generation system. The RF generator detects IMD components resulting from interaction of the two frequencies. The IMD is reduced by adjusting the phase of the RF signal output by the RF generator. In various configurations, the IMD may also be reduced by applying a power adjustment value.
    Type: Grant
    Filed: January 21, 2018
    Date of Patent: April 23, 2019
    Assignee: MKS Instruments, Inc.
    Inventors: David J. Coumou, Dennis M. Brown, Eldridge M. Mount, IV
  • Patent number: 10229816
    Abstract: An eVC including coarse and fine tuning networks. The coarse tuning network includes a circuit: receiving a RF input signal from a RF generator; outputting a RF output signal to a reference terminal or load; and receiving a DC bias voltage. The circuit is switched between first and second states. A capacitance of the circuit is based on the DC bias voltage while in the first state and is not based on the DC bias voltage while in the second state. The fine tuning network is connected in parallel with the coarse tuning network and includes a varactor. The varactor includes: a first diode receiving the RF input signal; and a second diode connected in a back-to-back configuration with the first diode and outputting a RF output signal to the reference terminal or load. A capacitance of the varactor is based on a second received DC bias voltage.
    Type: Grant
    Filed: May 24, 2016
    Date of Patent: March 12, 2019
    Assignee: MKS Instruments, Inc.
    Inventors: David J. Coumou, Dennis M Brown, Aaron T. Radomski, Mariusz Oldziej, Yogendra K. Chawla, Daniel J. Lincoln
  • Publication number: 20190068158
    Abstract: A single input multiple output plasma control system includes a splitter that receives a single input and generates multiple outputs. Each output from the splitter is provided to a load. The splitter includes branch circuits connected between selected splitter outputs. The branch circuits control voltage, current, power, frequency, or phase between each branch to enable controlling a predetermined relationship between the voltage, current, power, impedance, frequency, or phase measured at each load.
    Type: Application
    Filed: August 24, 2018
    Publication date: February 28, 2019
    Inventors: David J. COUMOU, Dennis M. BROWN, Jeongseok JANG, Jin HUH
  • Patent number: 10201521
    Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of glioblastoma multiforme and medulloblastoma. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: February 12, 2019
    Assignee: Del Mar Pharmaceuticals (BC) Ltd.
    Inventors: Dennis M. Brown, Jeffrey Bacha, Sandra Dunn
  • Publication number: 20190015379
    Abstract: The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and for the treatment of glioblastoma multiforme (GBM). Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide; the drug acts independently of the MGMT repair mechanism.
    Type: Application
    Filed: November 10, 2015
    Publication date: January 17, 2019
    Inventors: Jeffrey A. BACHA, Dennis M. BROWN, Anne STEINØ, Shaun FOUSE